Proof-of-concept data on new ingestible technologies
At Digestive Disease Week® 2019 in San Diego, we presented results from three proof-of-concept studies that represent potential breakthrough systems for diagnosing, treating, and monitoring digestive diseases through ingestible technologies.
Development of an Ingestible Diagnostic Capsule to Monitor
Biora presented results of a study evaluating the function of a system that includes an autonomous, swallowable diagnostic capsule for in situ biomolecular detection. As a proof of concept, this system has been designed to aid in the diagnosis and monitoring of small intestinal bacterial overgrowth (SIBO). The system has three components: a capsule, a wearable receiver, and analysis software. The capsule is a single-use device swallowed by the patient. The capsule determines its location in the digestive tract, collects a sample, and performs an onboard assay to measure bacterial load. The results of the assay are wirelessly communicated from the wearable receiver to the software for review by the healthcare provider.
Direct Topical Delivery of Monoclonal Antibodies Could Improve
Treatment of IBD
Two posters presented by Biora hypothesize that improved treatment response for Inflammatory Bowel Disease (IBD) can be achieved via direct topical delivery of monoclonal antibodies (mAbs) directly to the site of disease. This can be achieved by providing concentrations sufficient to drive improved efficacy while reducing the systemic toxicity that is often associated with these agents when administered systemically. Taken together, these findings provide a proof of concept for direct topical delivery of therapeutic antibodies, and suggest the potential for improved efficacy in the treatment of IBD.
Development of Targeted Therapeutic Antibodies for the Treatment of Inflammatory Bowel Disease
A Comparison Study of Systemic Versus Targeted Intracecal Anti-TNF∝ Monoclonal Antibody in an Adoptive T-cell Transfer Murine Model of Colitis